登录后查看消息通知
搜索
常见问题
消息
登录
首页
/
数据集
/
Reactogenicity after rAd5 boost by study group.
Reactogenicity after rAd5 boost by study group.
收藏
NIAID Data Ecosystem
2026-03-07 收录
疫苗反应原性
临床试验安全性
数据链接：
https://figshare.com/articles/dataset/_Reactogenicity_after_rAd5_boost_by_study_group_/407651
数据链接
链接失效反馈
官方服务：
问题咨询
购买咨询
在线客服
NEW
资源简介：
Reactogenicity after rAd5 boost by study group.
应用场景：
创建时间：
2011-09-12
相关数据集
Demographic and baseline characteristics (safety set).
临床试验安全性
患者基线特征
Demographic and baseline characteristics (safety set).
NIAID Data Ecosystem
9
0
Treatment-related Adverse Events (AE).
药物不良反应监测
临床试验安全性
Events are listed alphabetically with percentages indicating percent of total AEs. Grading is according to standard Common Terminology Criteria for Adverse Events (CTCAE) grading.
Figshare
2015-12-02 更新
5
0
Serious adverse events by randomisation arm.
临床试验安全性
不良事件分析
Serious adverse events by randomisation arm.
Figshare
2018-11-27 更新
3
0
Summary of Number of participants experiencing grade 3–4 AEs, SAEs or death by treatment and baseline CLcr (mL/min) groups through 96 weeks.
临床试验安全性
肾功能分层
Summary of Number of participants experiencing grade 3–4 AEs, SAEs or death by treatment and baseline CLcr (mL/min) groups through 96 weeks.
NIAID Data Ecosystem
6
0
Serious adverse events (all) and adverse events (with more than 2% of patients experiencing them) between the intervention groups.
临床试验安全性
不良事件分析
Serious adverse events (all) and adverse events (with more than 2% of patients experiencing them) between the intervention groups.
Figshare
2022-01-18 更新
5
0
© 2023-2026 上海数据发展科技有限责任公司 版权所有
沪ICP备17003045号-15
沪公网安备31010402336585号
热门搜索
社区交流群
科研交流群
商业服务
数据资源
寻源服务
数据采集
标注服务
数据产品
代理销售
数据领域
凭证登记
数据产品
介绍推广
